RSS-Feed abonnieren
DOI: 10.1055/s-0030-1257704
Messung der Lebensqualität bei Patienten mit Lungenkarzinom: Aktualisierung des Fragebogenmoduls EORTC QLQ-LC13
Publikationsverlauf
Publikationsdatum:
02. Januar 2012 (online)
![](https://www.thieme-connect.de/media/dzo/201104/lookinside/thumbnails/10.1055-s-0030-1257704-1.jpg)
Zusammenfassung
Das EORTC QLQ-LC13 war das erste Lebensqualitätsfragebogen-Modul, das zusammen mit dem Kernfragebogen QLQ-C30 entwickelt und 1994 veröffentlicht wurde. Seit der Entwicklung des QLQ-LC13 Moduls haben sich einige neue Erkenntnisse in der Epidemiologie und erhebliche Fortschritte in der Diagnostik und Therapie des Lungenkarzinoms ergeben. Das überarbeitete Fragebogenmodul soll im Kontext aller aktuell möglichen diagnostischen und therapeutischen Optionen entstehen, für alle unterschiedlichen Lungenneoplasien (kleinzelliges Lungenkarzinom – SCLC, nicht kleinzelliges Lungenkarzinom – NSCLC) in metastasierten und nicht metastasierten Stadien verwendbar sein und generelle Aspekte der Lebensqualität für Lungenkarzinompatienten einbeziehen. Methodische Grundlage für die Überarbeitung ist das Phase 1–3 Schema gemäß dem EORTC Modulentwicklungs-Manual.
Summary
Assessment of quality of life in patients with lung cancer: Updating the questionnaire module EORTC QLQ-LC13
EORTC QLQ-LC13 was the first questionnaire module that was developed in conjunction with the cancer-related core questionnaire QLQ-C30 and was published in 1994. Since the development of the QLQ-LC13, the body of knowledge about the epidemiology of lung cancer has grown and diagnostic and therapeutic options have vastly improved. The new questionnaire module will be developed in the context of state-of-the-art diagnostic and therapeutic options, should be applicable to all types of lung cancer (small cell lung cancer – SCLC, non-small cell lung cancer – NSCLC) in metastasized and non-metastasized stages and should also include general aspects of quality of life of lung cancer patients that had been neglected so far. The research methodology is based on the Phase 1 to 3 scheme according to the EORTC module development manual.
-
Literatur
- 1 Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994; 30A: 635-42
- 2 Boda-Heggemann J et al. Kv Cone-Beam CT-based IGRT. Strahlenther Onkol 2011; 187: 284-91
- 3 Bowling A. Measuring Disease. A Review of Disease-Specific Quality of Life Measurement Scales. 2nd ed. Buckingham: Open University Press; 2001
- 4 Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-40
- 5 Claasens L, Van Meerbeek J, Coens C et al. Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 2011; 29: 2104-20
- 6 Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A. on behalf of the EORTC Quality of Life Group. EORTC Quality of Life Group Translation Procedure (Translation Manual). 3rd. ed. Brussels: EORTC; 2009
- 7 FDA & US Department of Health and Human Services. Guidance for Industry. Patient-reported outcome measures: Use in medical product development to support labeling claims 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
- 8 Garrod R, Bestall JC, Paul EA et al. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med 2000; 94: 589-96
- 9 Goeckenjan G et al. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2010; 64 Supplement 2: e1–e164
- 10 Guckenberger M et al. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advaced NSCLC. Int J Rad Oncol Biol Phys 2011; 79: 901-8
- 11 Gujral S, Conroy T, Fleissner C et al. Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire. Eur J Cancer 2007; 43: 1564-73
- 12 Henoch I, Bergman B, Gaston-Johansson F. Validation of a Swedish version of the Cancer Dyspnea Scale. J Pain Symptom Manage 2006; 31: 353-61
- 13 Herth FJ, Eberhardt R. Actual role of endobronchial ultrasound (EBUS). Eur Radiol 2007; 17: 1806-12
- 14 Hollen PJ, Gralla RJ, Kris MG et al. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1999; 7: 140-8
- 15 Hollen PJ, Gralla RJ, Kris MG et al. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1994; 2: 213-22
- 16 International Agency for Research on Cancer (IARC). Tobacco Smoke and Involuntary Smoking. Lyon: World Health Organization; 2004
- 17 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
- 18 Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7
- 19 Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, Johnson C, Ramage J, Scott N, West K. on behalf of the EORTC Quality of Life Group. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 2007; 43: 1810-20
- 20 McDowell I. Measuring Health. A Guide to Rating Scales and Questionnaires. 3rd ed. Oxford: Oxford Univ. Press; 2006
- 21 Pompili C, Brunelli A, Xiumé F et al. Prospective external convergence evaluation of two different quality-of-life instruments in lung resection patients. Eur J Cardiothorac Surg 2011; 40: 99-105
- 22 Preedy VR, Watson RR. Handbook of Disease Burdens and Quality of Life Measures. New York: Springer; 2010. http://www.springerlink.com/content/978-0-387-78665-0
- 23 Puhan MA, Guyatt GH, Goldstein R et al. Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 2007; 101: 308-16
- 24 Salvo N, Hadi S, Napolskikh J et al. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Curr Oncol 2009; 16: 16-28
- 25 Sanjuas C, Alonso J, Prieto L et al. Health-related quality of life in asthma: a comparison between the St George's Respiratory Questionnaire and the Asthma Quality of Life Questionnaire. Qual Life Res 2002; 11: 729-38
- 26 Schumacher J, Klaiberg A, Brähler E. Diagnostische Verfahren zu Lebensqualität und Wohlbefinden. Göttingen: Hogrefe; 2003
- 27 Simonato L, Agudo A, Ahrens W et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 2001; 91: 876-87
- 28 Sprangers MA, Cull A, Groenvold M et al. The European organization for research and treatment of cancer approach to developing questionnaire modules. An update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998; 7: 291-300
- 29 Tanaka K, Akechi T, Okuyama T et al. Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manage 2002; 23: 484-97
- 30 Vachalec S, Bjordal K, Bottomley A, Blazeby J, Flechtner H, Ruyskart P. EORTC Item Bank Guidelines. Brussels: EORTC Quality of Life Group; 2001
- 31 van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-93